Beijing Luzhu Biotechnology Co (HKSE:02480) EBIT: HK$-157.96 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02480 Beijing Luzhu Biotechnology Co Ltd HKSE:02480
24 GF Score
Price HK$13.00
! 3 Warning Signs
View Full Analysis

What is Beijing Luzhu Biotechnology Co EBIT?

Beijing Luzhu Biotechnology Co HKSE:02480 24 EBIT is HK$-157.96 Mil as of Dec. 2025. GuruFocus rates HKSE:02480 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Beijing Luzhu Biotechnology Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-76.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-157.96 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing Luzhu Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2025 was -21.94%. Beijing Luzhu Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -23.28%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Beijing Luzhu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -6.54%.

Beijing Luzhu Biotechnology Co  (HKSE:02480) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing Luzhu Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-153.656 * ( 1 - 0% )/( (685.907 + 714.982)/ 2 )
=-153.656/700.4445
=-21.94 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1175.12 - 91.563 - ( 482.471 - max(0, 106.723 - 504.373+482.471))
=685.907

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1148.463 - 79.92 - ( 463.389 - max(0, 130.872 - 484.433+463.389))
=714.982

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing Luzhu Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-152.29/( ( (655.778 + max(-89.38, 0)) + (652.356 + max(-68.793, 0)) )/ 2 )
=-152.29/( ( 655.778 + 652.356 )/ 2 )
=-152.29/654.067
=-23.28 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 4.807 + 0) - (91.563 + 0 + 2.624)
=-89.38

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.41 + 4.031 + 14.989) - (79.92 + 0 + 8.303)
=-68.793

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beijing Luzhu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-157.955/2416.936
=-6.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co EBIT Related Terms

Beijing Luzhu Biotechnology Co EBIT Historical Data

* Premium members only.

The historical data trend for Beijing Luzhu Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co EBIT Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-659.69 -809.01 -271.81 -178.80 -158.83

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only -185.44 -117.93 -61.85 -81.81 -76.15

HKSE:02480 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Luzhu Biotechnology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's EV-to-EBIT falls into.


HKSE:02480
24GF Score
Beijing Luzhu Biotechnology Co Ltd HKSE:02480
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Luzhu Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-157.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-157.96 Mil mean?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a EBIT of HK$-157.96 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beijing Luzhu Biotechnology Co.
Is Beijing Luzhu Biotechnology Co's EBIT too high?
Beijing Luzhu Biotechnology Co's current EBIT is HK$-157.96 Mil. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's EBIT compare to VRTX and REGN?
Beijing Luzhu Biotechnology Co's EBIT of HK$-157.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beijing Luzhu Biotechnology Co. Beijing Luzhu Biotechnology Co's current EBIT is HK$-157.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current EBIT of HK$-157.96 Mil. The current EBIT is HK$-157.96 Mil. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current EBIT is HK$-157.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Luzhu Biotechnology Co Business Description

Address No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score

Get the complete analysis for HKSE:02480

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$13.00
Price